DOCSLIB.ORG

Annual Report and Financial Statements 2020 Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report and Financial Statements 2020 Table of Contents Annual Report and Financial Statements 2020 Table of contents Report from Chair 3 Report from Director 5 Trustee’s Report 7 What we do 8 Year at a glance 9 Review of Charitable Activities 11 Review of Investment Activities 24 Financial Review 34 Structure and Governance 39 Social Responsibility 45 Risk Management and Internal Control 47 Remuneration Report 51 Remuneration Committee Report 53 Nominations and Governance Committee Report 54 Investment Committee Report 55 Audit and Risk Committee Report 56 Independent Auditor’s Report 59 Financial Statements 68 Consolidated Statement of Financial Activities 69 Consolidated Balance Sheet 70 Statement of Financial Activities of the Trust 71 Balance Sheet of the Trust 72 Consolidated Cash Flow Statement 73 Alternative Performance Measures and Key Performance Indicators 74 Glossary of Terms 75 Notes to the Financial Statements 76 Reference and Administrative Details 124 Table of Contents Wellcome Trust Annual Report 2020 | 2 Report from Chair Wellcome has played a key role in the global international partnerships and initiatives. As one research response to the pandemic this year, example (there are too many to list), Wellcome while supporting research to improve health in and UNITAID are convening the therapeutics pillar a variety of ways, maintaining a consistent level of the World Health Organization’s Access to of charitable spending, and increasing the value Covid-19 Tools Accelerator. of our investments portfolio. Investments This has been an immensely challenging year. Covid-19 has tested governments to the limits as Wellcome’s capacity to act is dependent on how they have struggled to save lives and maintain well the organisation is run and the skill with livelihoods. The effects on the economy, people’s which our investment team manages the portfolio mental health, other diseases, and world politics that funds everything we do. During my time at have been profound. Wellcome, the value of the investments portfolio has more than doubled, valued at £29 billion on Soon after I joined Wellcome, during a visit by 30 September 2020, allowing a substantial increase the Board of Governors to a Wellcome-funded in charitable spending over the past decade. research centre in Vietnam, the scientist leading the Wellcome is an active and long-term investor: centre arranged a lecture on the 1918 flu pandemic. decisions are based on the continuing ‘licence to I only later appreciated its significance: his concern operate’ of the businesses and funds in which we that we were unprepared for another. That scientist invest. This year, the Board agreed that extra weight was Jeremy Farrar, who became Director of should be placed on sustainability and energy Wellcome in 2013. Among other achievements, he transition when assessing licence to operate. soon ensured that Wellcome co-founded with the The Board has been immensely impressed by how governments of Germany, Japan, India and Norway, the team has navigated with confidence the threat the Bill and Melinda Gates Foundation and the to the world economy caused by Covid-19 this World Economic Forum – the Coalition of Epidemic year. Locking down major economies put huge Preparedness Innovations (CEPI). strains on many businesses in which we invest and “The world needs strong, on financial markets, while accelerating important economic trends such as the shift to e-commerce. compassionate leadership” Equity markets endured one of the steepest declines and fastest recoveries in financial history. So when we first heard of a novel disease in Despite this, the portfolio has not just survived, Wuhan at the end of 2019, Wellcome, with its but prospered in this highly volatile environment, investment in CEPI and with Vaccines one of our returning 12.3% in the year to 30 September 2020 priorities, was better prepared than some for what (11.1% after inflation). lay ahead. And CEPI was able to start funding The macro environment of course remains vaccine work as soon as researchers in China challenging, not least because governments had published the genome of the virus in January. everywhere will need to find ways of reducing the Jeremy, with his experience of SARS, pandemic enormous debt burdens taken on to combat the influenza and other epidemics, and having led Covid-19 crisis. Market valuations are extremely Wellcome’s response to Ebola and Zika, has stretched with interest rates at unprecedently offered outstanding leadership, helping Wellcome low levels. The portfolio is likely to face more and many others understand and address the challenging times ahead, so the team is working pandemic. He has given Wellcome the means and hard to ensure that we are as well placed as the ambition to take an active role in a number of possible to face more difficult times. Report from Chair Wellcome Trust Annual Report 2020 | 3 Strategy Board of Governors Over the course of this year, the Executive has Covid-19 has meant a dramatic end to my time developed and launched a new strategy for at Wellcome. My thanks go to the Board of Wellcome. This was in gestation long before Governors and the Executive Leadership Team for Covid-19 as we sought, in consultation with many, continuing to make bold decisions in a time of to plan how best to use Wellcome’s independence great uncertainty and online meetings. Bill Burns and resources for the greatest effect in improving retired from the Board after four years and his human health. We chose three challenges, mental wisdom and humour will be missed. In January health, global heating, and escalating infectious 2020, Elhadj As Sy joined the Board, and we are diseases. This choice was reinforced by the already extremely grateful for his perspectives on pandemic, which also emphasised their linkages. health, policy and the pandemic response. The pandemic has shown that solving these I am delighted that the Board has chosen Julia challenges, or perhaps more realistically, Gillard to replace me and I wish her and Wellcome significantly reducing their damage, requires further success in the years ahead. It has been unprecedented international cooperation. And we an enormous privilege to be part of what is an shall never undervalue the vital role of discovery extraordinary organisation. There are many science, of backing scientists to explore our challenges ahead, and the world needs strong, understanding of human health and how to compassionate leadership. Wellcome has a role to improve it. Without their sometimes serendipitous play, supporting science and finding solutions to discoveries, across a wide range of disciplines, urgent worldwide health issues. I pay tribute to the often with new tools, progress would be slight. people at Wellcome, the increasing professionalism of its culture, and the renewed sense of purpose But we are not just a funder, as our work on that comes with a new vision and strategy. Covid-19, for example, shows where we have convened partners across the world, helped raise billions of pounds from public, private and philanthropic sectors to fund research, and argued for what we judge is important. I hope we will always continue to make our voice heard, Eliza Manningham-Buller including on the value of strong links between Chair of Wellcome British science and Europe after Brexit. Implementing the strategy will take some time as necessary changes are made to the internal organisational design and culture, as well as to funding mechanisms and other activities, over the coming year or two. As part of this work, we are continuing to develop performance indicators against which to judge future progress. This process is making it easier for us to put diversity at the heart of everything we do, from the staff we employ to the research we fund and the goals we set. The resurgence of the Black Lives Matter movement this summer highlighted existing challenges for people of colour, including within the research community and within Wellcome. It was an opportunity to examine ourselves critically, strengthen Wellcome’s commitment to anti-racism, and take a more proactive approach to changing some of the systemic issues that hinder diversity and equity in health, in research culture, and in our own organisation. Report from Chair Wellcome Trust Annual Report 2020 | 4 Report from Director A difficult year has ended with fresh hopes for Wellcome’s role in the global response to Covid-19 the future thanks to researchers across the and the necessary closures of our buildings world. Wellcome has a renewed commitment meant some of our more usual activities had to to supporting science and bringing people be delayed or cancelled this year. This allowed us together to solve the urgent and truly global to maintain day-to-day operations and a strong challenges to all our health. control environment while working remotely, and demonstrated a robust level of operational On 30 September 2020, the end of Wellcome’s resilience, for which I thank all of my colleagues. financial year, the number of confirmed deaths Everyone had to adapt to a greater or lesser from Covid-19 had just passed 1 million worldwide degree because of reprioritised work, available – each life lost an individual tragedy caught up in space, caring responsibilities, health or other one of the most momentous events of the last reasons. Our position was clear: people’s first 100 years. Many millions more are now living with responsibility was to themselves and their family long-term effects on their health after infection, and friends. Work comes second at times like this. while all of us are grappling with restrictions on our normal ways of life. The environment in which we operate remains uncertain and changeable. Local and national public Since then, however, trial results have indicated a health measures will continue to apply for a good strong likelihood that in 2021 we will have several while yet, in phases of tighter or looser restrictions, safe, effective vaccines to help protect us from and we will respond accordingly.
Load more

Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents
    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
    [Show full text]
  • The Electron Microscopy Science Technology Platform at the Francis
    The Francis Crick Institute is a The Electron biomedical discovery institute Microscopy dedicated to understanding the fundamental biology underlying Science health and disease. Its work Technology is helping to understand why disease develops and to translate Platform at discoveries into new ways to the Francis prevent, diagnose and treat illnesses such as cancer, heart Crick Institute disease, stroke, infections, and Lucy Collinson neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, University College London, Imperial College London and King’s College London. The Crick was formed in 2015, with many of the Crick’s scientists joining from two ‘parent’ institutes, the MRC’s National Institute for Medical Research and Cancer Research UK’s London Research Institute, and in 2016 it moved into a brand new state-of- the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe. © Nick Guttridge 4 ISSUE 46 JUNE 2017 5 Each microscope room is a six-sided shielded box, • The Phenom-World DelPhi benchtop SEM with walls that contain complex metallic layers has an integrated fluorescence microscope to attenuate DC fields, and an active cancellation for correlative imaging system to attenuate AC fields. Under each • The FEI Twin 120 kV TEM has a cryo stage for microscope is a concrete platform, cast in place, and screening vitrified macromolecular samples supported by air springs that remove environmental prior to imaging on 200 kV and 300 kV TEMs vibration to <1 Hz.
    [Show full text]
  • A Short History of the Royal Aeronautical Society
    A SHORT HISTORY OF THE ROYAL AERONAUTICAL SOCIETY Royal Aeronautical Society Council Dinner at the Science Museum on 26 May 1932 with Guest of Honour Miss Amelia Earhart. Edited by Chris Male MRAeS Royal Aeronautical Society www.aerosociety.com Afterburner Society News RAeS 150th ANNIVERSARY www.aerosociety.com/150 The Royal Aeronautical Society: Part 1 – The early years The Beginning “At a meeting held at Argyll Lodge, Campden Hill, Right: The first Aeronautical on 12 January 1866, His Grace The Duke of Argyll Exhibition, Crystal Palace, 1868, showing the presiding; also present Mr James Glaisher, Dr Hugh Stringfellow Triplane model W. Diamond, Mr F.H. Wenham, Mr James Wm. Butler and other exhibits. No fewer and Mr F.W. Brearey. Mr Glaisher read the following than 77 exhibits were address: collected together, including ‘The first application of the Balloon as a means of engines, lighter- and heavier- than-air models, kites and ascending into the upper regions of the plans of projected machines. atmosphere has been almost within the recollection A special Juror’s Report on on ‘Aerial locomotion and the laws by which heavy of men now living but with the exception of some the exhibits was issued. bodies impelled through air are sustained’. of the early experimenters it has scarcely occupied Below: Frederick W Brearey, Wenham’s lecture is now one of the aeronautical Secretary of the the attention of scientific men, nor has the subject of Aeronautical Society of Great classics and was the beginning of the pattern of aeronautics been properly recognised as a distinct Britain, 1866-1896.
    [Show full text]
  • Structure of Human Aspartyl Aminopeptidase Complexed With
    Chaikuad et al. BMC Structural Biology 2012, 12:14 http://www.biomedcentral.com/1472-6807/12/14 RESEARCH ARTICLE Open Access Structure of human aspartyl aminopeptidase complexed with substrate analogue: insight into catalytic mechanism, substrate specificity and M18 peptidase family Apirat Chaikuad1, Ewa S Pilka1, Antonio De Riso2, Frank von Delft1, Kathryn L Kavanagh1, Catherine Vénien-Bryan2, Udo Oppermann1,3 and Wyatt W Yue1* Abstract Backround: Aspartyl aminopeptidase (DNPEP), with specificity towards an acidic amino acid at the N-terminus, is the only mammalian member among the poorly understood M18 peptidases. DNPEP has implicated roles in protein and peptide metabolism, as well as the renin-angiotensin system in blood pressure regulation. Despite previous enzyme and substrate characterization, structural details of DNPEP regarding ligand recognition and catalytic mechanism remain to be delineated. Results: The crystal structure of human DNPEP complexed with zinc and a substrate analogue aspartate-β- hydroxamate reveals a dodecameric machinery built by domain-swapped dimers, in agreement with electron microscopy data. A structural comparison with bacterial homologues identifies unifying catalytic features among the poorly understood M18 enzymes. The bound ligands in the active site also reveal the coordination mode of the binuclear zinc centre and a substrate specificity pocket for acidic amino acids. Conclusions: The DNPEP structure provides a molecular framework to understand its catalysis that is mediated by active site loop swapping, a mechanism likely adopted in other M18 and M42 metallopeptidases that form dodecameric complexes as a self-compartmentalization strategy. Small differences in the substrate binding pocket such as shape and positive charges, the latter conferred by a basic lysine residue, further provide the key to distinguishing substrate preference.
    [Show full text]
  • Rare Variant Contribution to Human Disease in 281,104 UK Biobank Exomes W ­ 1,19 1,19 2,19 2 2 Quanli Wang , Ryan S
    https://doi.org/10.1038/s41586-021-03855-y Accelerated Article Preview Rare variant contribution to human disease W in 281,104 UK Biobank exomes E VI Received: 3 November 2020 Quanli Wang, Ryan S. Dhindsa, Keren Carss, Andrew R. Harper, Abhishek N ag­­, I oa nn a Tachmazidou, Dimitrios Vitsios, Sri V. V. Deevi, Alex Mackay, EDaniel Muthas, Accepted: 28 July 2021 Michael Hühn, Sue Monkley, Henric O ls so n , S eb astian Wasilewski, Katherine R. Smith, Accelerated Article Preview Published Ruth March, Adam Platt, Carolina Haefliger & Slavé PetrovskiR online 10 August 2021 P Cite this article as: Wang, Q. et al. Rare variant This is a PDF fle of a peer-reviewed paper that has been accepted for publication. contribution to human disease in 281,104 UK Biobank exomes. Nature https:// Although unedited, the content has been subjectedE to preliminary formatting. Nature doi.org/10.1038/s41586-021-03855-y (2021). is providing this early version of the typeset paper as a service to our authors and Open access readers. The text and fgures will undergoL copyediting and a proof review before the paper is published in its fnal form. Please note that during the production process errors may be discovered which Ccould afect the content, and all legal disclaimers apply. TI R A D E T A R E L E C C A Nature | www.nature.com Article Rare variant contribution to human disease in 281,104 UK Biobank exomes W 1,19 1,19 2,19 2 2 https://doi.org/10.1038/s41586-021-03855-y Quanli Wang , Ryan S.
    [Show full text]
  • A Critical Base Pair in K-Turns That Confers Folding Characteristics and Correlates with Biological Function
    ARTICLE Received 16 Apr 2014 | Accepted 2 Sep 2014 | Published 29 Oct 2014 DOI: 10.1038/ncomms6127 OPEN A critical base pair in k-turns that confers folding characteristics and correlates with biological function Scott A. McPhee1, Lin Huang1 & David M.J. Lilley1 Kink turns (k-turns) are widespread elements in RNA that mediate tertiary contacts by kinking the helical axis. We have found that the ability of k-turns to undergo ion-induced folding is conferred by a single base pair that follows the conserved AG pairs, that is, the 3b3n position. A Watson–Crick pair leads to an inability to fold in metal ions alone, while 3n ¼ Gor3b¼ C (but not both) permits folding. Crystallographic study reveals two hydrated metal ions coordinated to O6 of G3n and G2n of Kt-7. Removal of either atom impairs Mg2 þ - induced folding in solution. While SAM-I riboswitches have 3b3n sequences that would predispose them to ion-induced folding, U4 snRNA are strongly biased to an inability to such folding. Thus riboswitch sequences allow folding to occur independently of protein binding, while U4 should remain unfolded until bound by protein. The empirical rules deduced for k-turn folding have strong predictive value. 1 Cancer Research UK Nucleic Acid Structure Research Group, MSI/WTB Complex, The University of Dundee, Dow Street, Dundee DD1 5EH, UK. Correspondence and requests for materials should be addressed to D.M.J.L. (email: [email protected]). NATURE COMMUNICATIONS | 5:5127 | DOI: 10.1038/ncomms6127 | www.nature.com/naturecommunications 1 & 2014 Macmillan Publishers Limited.
    [Show full text]
  • The ELIXIR Core Data Resources: ​Fundamental Infrastructure for The
    Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure ​ for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). ​ ​ Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences ​ 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that ​ ​ mention Core Data Resource by name or include specific data record accession numbers.
    [Show full text]
  • Open Targets Genetics
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Open Targets Genetics: An open approach to systematically prioritize causal variants 2 and genes at all published GWAS trait-associated loci 3 4 Edward Mountjoy1,2, Ellen M. Schmidt1,2, Miguel Carmona2,3, Gareth Peat2,3, Alfredo Miranda2,3, 5 Luca Fumis2,3, James Hayhurst2,3, Annalisa Buniello2,3, Jeremy Schwartzentruber1,2,3, Mohd 6 Anisul Karim1,2, Daniel Wright1,2, Andrew Hercules2,3, Eliseo Papa4, Eric Fauman5, Jeffrey C. 7 Barrett1,2, John A. Todd6, David Ochoa2,3, Ian Dunham1,2,3, Maya Ghoussaini1,2,*. 8 9 1. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 10 1SA, UK 11 2. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 12 3. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), 13 Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 14 4. Systems Biology, Biogen, Cambridge, MA, 02142, United States 15 5. Integrative Biology, Internal Medicine Research Unit, Pfizer Worldwide Research, 16 Development and Medical, Cambridge, MA 02139, United States 17 6. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford 18 Biomedical Research Centre, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, 19 UK 20 * Corresponding author 21 22 23 24 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020.
    [Show full text]
  • Evidence Synthesis on the EU-UK Relationship on Research and Innovation January 2018
    Evidence synthesis on the EU-UK relationship on research and innovation January 2018 1. Introduction The Royal Society and the Wellcome Trust have undertaken a rapid evidence synthesis on the EU-UK research and innovation relationship as part of their Future Partnership Project. Organisations and individuals were invited to submit evidence and analyses for inclusion. Evidence was also gathered through internet searches to ensure an inclusive approach. The Annex is a summary of the methods. Two questions were used in gathering evidence and in determining the material in scope: 1. What incentives, infrastructure and mechanisms can be accessed by research and innovation organisations, funders and individuals in Member States to support collaborations? 2. How do Member States currently use and benefit from these and how might they be affected by Brexit? This paper is a synthesis of the evidence and covers funding, infrastructures, mobility, collaboration and regulation, with a focus on links between the EU and the UK. 2. Overview of the evidence base A few major reports were of particular relevance; the Royal Society’s three reports on the role of the EU in UK research and innovation and two reports commissioned from Technopolis Group by UK organisations, on the role of EU funding in UK research and innovation and the impact of collaboration: the value of UK medical research to EU science and health1,2. These documents were often referenced in other submissions. A report from the Lords Science and Technology Committee’s inquiry on EU Membership and UK Science also summarises many sources of evidence relevant to this synthesis.
    [Show full text]
  • Select Committee on Science and Technology Corrected Oral Evidence: Ageing: Science, Technology and Healthy Living
    Select Committee on Science and Technology Corrected oral evidence: Ageing: science, technology and healthy living Tuesday 25 February 2020 10.20 am Watch the meeting Members present: Lord Patel (The Chair); Lord Borwick; Lord Browne of Ladyton; Baroness Hilton of Eggardon; Lord Kakkar; Lord Mair; Baroness Manningham-Buller; Baroness Penn; Viscount Ridley; Baroness Rock; Baroness Sheehan; Baroness Walmsley; Lord Winston; Baroness Young of Old Scone. Evidence Session No. 15 Heard in Public Questions 131 - 138 Witnesses Dame Fiona Caldicott, National Data Guardian; Matthew Gould, CEO, NHSX; Chris Roebuck, Chief Statistician, NHS Digital; Dr Jem Rashbass, Executive Director of Master Registries and Data, NHS Digital. USE OF THE TRANSCRIPT This is a corrected transcript of evidence taken in public and webcast on www.parliamentlive.tv. 1 Examination of witnesses Dame Fiona Caldicott, Matthew Gould, Chris Roebuck and Dr Jem Rashbass. Q131 The Chair: Good morning, Dame Fiona and gentlemen. Welcome and thank you for coming today to help us with this inquiry. There are some familiar faces to me; it is nice to see you. Before we start, would you mind introducing yourselves for the record from my left? If you want to make an opening statement, feel free to do so. If you have any interests to declare, please do so at the beginning. Chris Roebuck: I am the chief statistician at NHS Digital. I am accountable for the nearly 300 sets of official statistics we produce each year. These cover a range of health and care data, predominantly in England, including administrative data, clinical data and survey data. We release them to encourage transparency, to help with local and national decision-making and for public accountability.
    [Show full text]
  • Common Acronyms Engineers SOE Society of Operations Engineers Licensed Members TWI the Welding Institute BCS the Chartered Institute for IT
    SEE Society of Environmental Common Acronyms Engineers SOE Society of Operations Engineers Licensed Members TWI The Welding Institute BCS The Chartered Institute for IT BINDT British Institute of Non-Destructive Testing Professional Affiliates CIBSE Chartered Institution of Building ACostE Association of Cost Engineers Services Engineers APM Association for Project CIHT Chartered Institution of Highways Management and Transportation CABE Chartered Association of Building CIPHE Chartered Institute of Plumbing and Engineers Heating Engineering CQI Chartered Quality Institute CIWEM Chartered Institution of Water and IAEA Institute of Automotive Engineer Environmental Management Assessors EI Energy Institute IAT Institute of Asphalt Technology IAgrE Institution of Agricultural Engineers ICES Chartered Institution of Civil ICE Institution of Civil Engineers Engineering Surveyors IChemE Institution of Chemical Engineers ICorr Institute of Corrosion ICME Institute of Cast Metals Engineers ICT Institute of Concrete Technology IED Institution of Engineering IDE Institute of Demolition Engineers Designers IDGTE Institution of Diesel and Gas IET Institution of Engineering and Turbine Engineers Technology IExpE Institute of Explosives Engineers IFE Institution of Fire Engineers IMA Institute of Mathematics and its IGEM Institution of Gas Engineers and Applications Managers IMF Institute of Materials Finishing IHE Institute of Highway Engineers INCOSE UK International Council on Systems Engineering (UK Chapter) IHEEM Institute of Healthcare Engineering
    [Show full text]
  • Wellcome Trust Annual Report and Financial Statements 2018 Is © the Wellcome Trust and Is Licensed Under Creative Commons Attribution 2.0 UK
    Annual Report and Financial Statements 2018 Table of contents Report from Chair 3 Report from Director 4 Trustee’s Report 5 What we do 6 Review of Charitable Activities 7 Review of Investment Activities 18 Financial Review 28 Structure and Governance 33 Social Responsibility 38 Risk Management 40 Remuneration Report 42 Nomination Committee Report 44 Remuneration Committee Report 45 Investment Committee Report 46 Audit and Risk Committee Report 47 Independent Auditor’s Report 49 Financial Statements 59 Consolidated Statement of Financial Activities 60 Consolidated Balance Sheet 61 Statement of Financial Activities of the Trust 62 Balance Sheet of the Trust 63 Consolidated Cash Flow Statement 64 Notes to the Financial Statements 65 Reference and Administrative Details 116 2 Table of Contents Wellcome Trust Annual Report 2018 Report from Chair In March 2018, the Board of Governors and I year, driven by the performance of the investment decided to reappoint Jeremy Farrar as Director portfolio, which returned 13.4%, or 10.7% after of Wellcome for a further five years. Under his inflation. This year has seen a return of market leadership, Wellcome is ambitious, innovative and volatility as the economic cycle has matured. willing to take risks in pursuit of our mission of Central Banks, led by the US Federal Reserve, have improving health by helping great ideas to thrive. begun to raise interest rates and remove the prop to Wellcome’s work is underpinned by the financial asset prices previously provided by quantitative strength we derive from our £25.9 billion investment easing. Uncertainties about Brexit have generated portfolio.
    [Show full text]